ClinicalTrials.gg
CompletedNCT00613171Updated Jul 7, 2021Results posted

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

A Phase 2 interventional study of STI571 in Systemic Sclerosis, Scleroderma, sponsored by Novartis Pharmaceuticals. Completed at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.

Enrollment
85th of 142
27 · median 34
Started
2008
with 6 others
Phase 2
54 of 165
10 open now
Registered
25th of 165
by date

Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 85th largest by enrollment of the 142 interventional ones that give a count, is one of 7 that started in 2008, is one of 54 in phase 2, and was the 25th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Scleroderma, Systemic with a site in United States, or all of them as a file.
02

Study summary

This study investigates the efficacy and safety of STI571 for the treatment of fibrosis in participants with systemic sclerosis. Other purposes of the study were to investigate whether STI571 is effective in improving lung functions and other test results called biomarkers. Whether STI571 is well-absorbed in systemic sclerosis participants' gut was also investigated by testing the drug level in the blood (pharmacokinetics).

03

Conditions studied

  • Systemic Sclerosis, Scleroderma

Keywords

  • Systemic sclerosis, scleroderma, fibrosis, STI571, imatinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are equal to or older than 18 years of age and who have early diffuse cutaneous systemic sclerosis (Disease duration \< 18 months from the first non-Raynaud's symptom)
  • Participants with a modified Rodnans Skin Score (MRSS) of at least 20 in the absence of trunk involvement or a MRSS of at least 16 in patients with trunk involvement
  • Female patients of practicing two acceptable forms of

Exclusion criteria

Exclusion Criteria:

  • SSc patients with a MRSS greater than 35
  • Concurrent connective tissue diseases other than systemic sclerosis
  • Significant pre-existing heart, liver, lungs, digestive system, blood and other diseases, cancer
  • Conditions that might mimic the potential side effects of STI571 (blood conditions, liver damage, chronic diarrhea, edema)
  • Concurrent medical therapies (or during last 6 weeks before first dosing) that may potentially influence outcome of the study
  • Allergic to the study medication
  • Pregnancy
  • Breast feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    ST1571

    Participants received ST1571 100 mg tablets, orally, once daily. Initiated at an oral dose of 200 mg/day for 4 weeks then titrated up to 400 mg/day for 2 weeks followed by 600 mg/day until Week 24, if well tolerated.

    Drug: STI571

Interventions

  • DrugSTI571

    STI571 tablets taken orally once a day

    Also known as: Gleevec, Glivec

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Modified Rodnan Skin Score (MRSS) at Each Time Point of Analysis

    The efficacy of oral STI571 in participants with systemic sclerosis is defined by an improvement in MRSS. Skin thickness was assessed clinically in each of 17 body areas and scored using a 0-3 scale, where 0= normal, 1= mild thickness, 2= moderate thickness, and 3= severe thickness (maximum score 51). A higher score indicates greater severity of the disease.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and Week 48/End of Study (EOS)

  2. Number of Participants With Adverse Events (AE's) and Serious Adverse Events (SAE's)

    An AE is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to the study drug. An SAE is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization, is medically significant, i.e., defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Baseline to Week 48/EOS

Secondary outcomes

  1. Number of Participants With Non-response, Partial Response, Complete Response, and Remission Assessed by MRSS Values

    The following MRSS categories were calculated for up to Week 48: Non-response: a reduction in MRSS \<25%, Partial response: a reduction in MRSS between 25-\<50%, Complete response: a reduction in MRSS between 50-\<80%, Remission: a reduction in MRSS ≥80%.

    Time frame: Weeks 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and Week 48/End of Study (EOS)

07

Results

Posted May 21, 2021

Participant flow

This study was conducted at 7 centers in 5 countries from 02 January 2008 to 13 January 2010.

Participant flow — Overall Study
MilestoneSTI571
Started27
Completed13
Not completed14
Withdrew: Adverse event7
Withdrew: Withdrawal by subject3
Withdrew: Reason not specified4

Outcome measures

PrimaryChange From Baseline in Modified Rodnan Skin Score (MRSS) at Each Time Point of Analysis

The efficacy of oral STI571 in participants with systemic sclerosis is defined by an improvement in MRSS. Skin thickness was assessed clinically in each of 17 body areas and scored using a 0-3 scale, where 0= normal, 1= mild thickness, 2= moderate thickness, and 3= severe thickness (maximum score 51). A higher score indicates greater severity of the disease.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and Week 48/End of Study (EOS)
Reported as:
Mean · units on a scale
Change From Baseline in Modified Rodnan Skin Score (MRSS) at Each Time Point of Analysis
units on a scaleSTI571
Baseline25.7 ± 5.83
Week 26.58 ± 18.416
Week 45.97 ± 17.382
Week 68.34 ± 24.645
Week 88.48 ± 27.096
Week 123.34 ± 27.525
Week 1612.70 ± 28.399
Week 2012.41 ± 28.149
Week 249.90 ± 23.675
Week 28-3.17 ± 19.891
Week 32-5.67 ± 18.013
Week 36-12.61 ± 27.383
Week 40-5.23 ± 27.506
Week 44-13.57 ± 26.763
Week 48/ EOS-20.89 ± 24.946
PrimaryNumber of Participants With Adverse Events (AE's) and Serious Adverse Events (SAE's)

An AE is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to the study drug. An SAE is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization, is medically significant, i.e., defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
Baseline to Week 48/EOS
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE's) and Serious Adverse Events (SAE's)
ParticipantsSTI571
Participants Experiencing AE's27
Participants Experiencing SAE's5
SecondaryNumber of Participants With Non-response, Partial Response, Complete Response, and Remission Assessed by MRSS Values

The following MRSS categories were calculated for up to Week 48: Non-response: a reduction in MRSS \<25%, Partial response: a reduction in MRSS between 25-\<50%, Complete response: a reduction in MRSS between 50-\<80%, Remission: a reduction in MRSS ≥80%.

Time frame:
Weeks 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and Week 48/End of Study (EOS)
Reported as:
Count of participants · Participants
Number of Participants With Non-response, Partial Response, Complete Response, and Remission Assessed by MRSS Values
ParticipantsSTI571
Week 2 — Non-response27
Week 2 — Partial Response0
Week 2 — Complete Response0
Week 2 — Remission0
Week 4 — Non-response25
Week 4 — Partial Response2
Week 4 — Complete Response0
Week 4 — Remission0
Week 6 — Non-response24
Week 6 — Partial Response2
Week 6 — Complete Response1
Week 6 — Remission0
Week 8 — Non-response22
Week 8 — Partial Response2
Week 8 — Complete Response0
Week 8 — Remission0
Week 12 — Non-response15
Week 12 — Partial Response3
Week 12 — Complete Response0
Week 12 — Remission0
Week 16 — Non-response16
Week 16 — Partial Response2
Week 16 — Complete Response0
Week 16 — Remission0
Week 20 — Non-response16
Week 20 — Partial Response2
Week 20 — Complete Response0
Week 20 — Remission0
Week 24 — Non-response15
Week 24 — Partial Response1
Week 24 — Complete Response0
Week 24 — Remission0
Week 28 — Non-response13
Week 28 — Partial Response1
Week 28 — Complete Response0
Week 28 — Remission0
Week 32 — Non-response13
Week 32 — Partial Response1
Week 32 — Complete Response0
Week 32 — Remission0
Week 36 — Non-response9
Week 36 — Partial Response3
Week 36 — Complete Response0
Week 36 — Remission0
Week 40 — Non-response9
Week 40 — Partial Response3
Week 40 — Complete Response0
Week 40 — Remission0
Week 44 — Non-response8
Week 44 — Partial Response5
Week 44 — Complete Response0
Week 44 — Remission0
Week 48/EOS — Non-response5
Week 48/EOS — Partial Response8
Week 48/EOS — Complete Response0
Week 48/EOS — Remission0

Adverse events

Collected over Baseline to Week 48/EOS. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ST15710/27 (0%)5/27 (18.5%)27/27 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventST1571
NeutropeniaBlood and lymphatic system disorders1/27
Gastritis erosiveGastrointestinal disorders1/27
NauseaGastrointestinal disorders1/27
VomitingGastrointestinal disorders1/27
Face oedemaGeneral disorders1/27
Generalised oedemaGeneral disorders1/27
Oedema peripheralGeneral disorders1/27
Neutropenic infectionInfections and infestations1/27
Upper respiratory tract infectionInfections and infestations1/27
Viral infectionInfections and infestations1/27
Most frequent other events
Showing 10 of 139
Most frequent other events
EventST1571
Oedema peripheralGeneral disorders15/27
NauseaGastrointestinal disorders14/27
PruritusSkin and subcutaneous tissue disorders9/27
DiarrhoeaGastrointestinal disorders7/27
ArthralgiaMusculoskeletal and connective tissue disorders7/27
AnaemiaBlood and lymphatic system disorders6/27
VomitingGastrointestinal disorders5/27
Face oedemaGeneral disorders5/27
FatigueGeneral disorders5/27
HeadacheNervous system disorders5/27

Baseline characteristics

Efficacy analysis set included all participants who received at least one dose of the study drug with at least one post-baseline measurement.

Age, Continuous
Age, Continuous(years)STI571
Mean45.7 ± 11.99
Sex: Female, Male
Sex: Female, Male(Participants)STI571
Female21
Male6
08

Study locations

7 sites
  • Novartis Investigator Site
    Chicago, Illinois 60611, United States
  • Novartis Investigator Site
    Baltimore, Maryland 21224, United States
  • Novartis Investigator Site
    Boston, Massachusetts 02118, United States
  • Novartis Investigator Site
    Erlangen, Germany
  • Novartis Investigator Site
    Florence, Italy
  • Novartis Investigator Site
    Zurich, Switzerland
  • Novartis Investigator Site
    London, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2008 to primary completion in Jan 2010, 24 months.

Results were first posted in May 2021, 11 years 4 months after primary completion.

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2008
First posted
Feb 12, 2008
StartActual
Jan 2, 2008
Primary completionActual
Jan 13, 2010
CompletionActual
Jan 13, 2010
Results first posted
May 21, 2021
Last update
Jul 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00613171
Responsible party
Sponsor
First posted
Feb 12, 2008
Start date
Jan 2, 2008
Primary completion
Jan 13, 2010
Completion
Jan 13, 2010
Results posted
May 21, 2021
Last update
Jul 7, 2021

Study contacts

NOVARTIS
principal investigator · Novartis investigator site

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion